- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02014636
Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)
A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK 3475 in Patients With Advanced Renal Cell Carcinoma
This is an open-label, 2 part study of pazopanib and/or MK 3475 in treatment naïve subjects with advanced RCC. Part 1 consists of a Phase I dose escalation of pazopanib + MK 3475 followed by an expansion cohort to determine the maximum tolerated regimen and the recommended Phase II dose. Part 2 is a randomized 3-arm Phase II study to evaluate the clinical efficacy and safety of pazopanib + MK 3475 as compared to single-agent pazopanib and single-agent MK 3475. The objectives of this Phase I/II study are to test the safety and tolerability of pazopanib in combination with MK 3475, and study the clinical efficacy of pazopanib in combination with MK 3475 in subjects with advanced RCC as compared with single-agent pazopanib and single-agent MK 3475.
Following the Urgent Safety Measure (USM) released on February 09, 2017, the phase II (Part 2) portion of this study will not commence.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, W1G 6AD
- Novartis Investigative Site
-
-
Lancashire
-
Manchester, Lancashire, United Kingdom, M20 4BX
- Novartis Investigative Site
-
-
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Novartis Investigative Site
-
Boston, Massachusetts, United States, 02215
- Novartis Investigative Site
-
-
New York
-
New York, New York, United States, 10065
- Novartis Investigative Site
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed written informed consent before performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up
- Diagnosis of locally advanced or metastatic RCC that is predominantly clear cell histology
- Must have measurable disease
- Subject has received no prior systemic therapy
- A woman is eligible to participate in the study if she is of Non-childbearing potential, has a negative serum pregnancy test within 7 days of the first dose of study treatment, not lactating, and agrees to use adequate contraception during the study until at least 120 days after the last dose of investigational product
- Eastern Cooperative Oncology Group performance status 0 or 1
- Adequate organ function as defined in the protocol
- Left ventricular ejection fraction >= lower limit of normal as assessed by echocardiogram or multigated acquisition scan
- In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category
Exclusion Criteria:
- Subject has an active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents
- Subject is currently participating or has participated in a study of an investigational agent or using an investigational device within 30 days of the first dose of study treatment
- Subject is expected to require any other form of systemic or localized antineoplastic therapy while on study
- Subject is on any systemic steroid therapy, within one week before the planned date for first dose of study treatment. Subject is on any other form of immunosuppressive medication
- Subject has a history of a malignancy (other than the disease under treatment in the study) within 5 years before first study treatment administration
- Central nervous system metastasis
- Unable to swallow and retain orally administered medication
- Subject has interstitial lung disease or a history of pneumonitis
- Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other Gastrointestinal conditions with increased risk of perforation; history of abdominal fistula, GI perforation, or intra-abdominal abscess within 4 weeks before beginning study treatment
- Known history of HIV infection or a known history of or is positive for Hepatitis B or Hepatitis C
- Presence of active infection requiring systemic therapy
- Corrected QT interval duration prolongation
- History of any one or more of the following cardiac conditions within the past 6 months: Cardiac angioplasty or stenting; Myocardial infarction; Unstable angina; History of Class III or IV congestive heart failure according to New York Heart Association classification
- History of cerebrovascular accident within the past 6 months
- Poorly controlled hypertension
- History of untreated deep venous thrombosis
- Presence of any non-healing wound, fracture, or ulcer, or presence of symptomatic peripheral vascular disease
- Evidence of bleeding diathesis or coagulopathy
- Recent hemoptysis
- Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage
- Any serious and/or unstable pre-existing medical, psychiatric, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures
- Previous severe hypersensitivity reaction to another Monoclonal antibody. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the excipients in pazopanib tablets
- Has taken any prohibited medications that are listed in the protocol within 14 days of the first dose of study treatment. Subject has received or will receive a live vaccine within 30 days before the first administration of study treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1
Part 1 is a dose escalation phase in which subjects will receive pazopanib orally and the MK 3475 intravenously.
Subjects will be evaluated for a minimum of 8 weeks before the next dose level cohort is enrolled.
|
Pazopanib is an orally administered 200 mg tablet available in the dose range of 400 to 800 mg
MK 3475 is an intravenously administered 100 mg/ 4mL solution available in the potential dose range of 1 to 10 mg/kg.
|
Experimental: Part 2
Part 2 is a randomized phase in which subjects will be enrolled in each treatment arm: Pazopanib monotherapy Pazopanib+MK-3475 MK-3475 monotherapy |
Pazopanib is an orally administered 200 mg tablet available in the dose range of 400 to 800 mg
MK 3475 is an intravenously administered 100 mg/ 4mL solution available in the potential dose range of 1 to 10 mg/kg.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs )
Time Frame: From the start of study treatment (first dose) and, until the post-treatment follow-up visit (at least 30 days after the last dose of investigational product) for AEs, and until 90 days after last dose for SAEs
|
From the start of study treatment (first dose) and, until the post-treatment follow-up visit (at least 30 days after the last dose of investigational product) for AEs, and until 90 days after last dose for SAEs
|
|
Part 1: To determine the dose limiting toxicity (DLT) and maximum tolerated regimen (MTR)
Time Frame: 8 weeks
|
MTR is defined as the highest dose of pazopanib in combination with the highest dose of MK 3475 at which no more than 1 of 6 subjects experiences a DLT after a minimum of 8 weeks of treatment.
DLT is defined as a drug-related AE starting in the first 8 weeks of treatment
|
8 weeks
|
Part 1: Number of subjects with permanent discontinuation of treatment, dose reductions, interruptions, or delays
Time Frame: 24 months
|
24 months
|
|
Part 1: Change from baseline in laboratory parameters
Time Frame: Average of 4 years
|
Laboratory assessments include haematology, clinical chemistry, urine, coagulation and thyroid function test
|
Average of 4 years
|
Part 1: Change from baseline in vital signs
Time Frame: 30 days after the last dose of study treatment
|
Vital sign measurements will include heart rate, temperature and blood pressure
|
30 days after the last dose of study treatment
|
Part 1: Change from baseline in cardiac parameters
Time Frame: 24 months
|
Cardiac assessments will include Electrocardiogram (ECG) and Echocardiograms (ECHOs)
|
24 months
|
Part 1: Incidence and titer of anti MK 3475 antibodies
Time Frame: 24 months
|
Subjects will be monitored for anti-MK 3475 antibodies throughout the study
|
24 months
|
Part 2: Progression-free survival (PFS)
Time Frame: Average of 4 years
|
PFS is defined as the interval between the date of randomization and the earlier date of disease progression (using RECIST v1.1) or death due to any cause.
|
Average of 4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: Dose escalation cohorts: pazopanib plasma concentrations and serum MK 3475 concentrations.
Time Frame: For Pazopanib: before and after the 1st and 2nd dose of MK-3475. For MK-3475: Until 6 months after the last dose of MK-3475
|
For analysis of plasma pazopanib and serum MK 3475 concentrations, blood samples will be collected from all subjects
|
For Pazopanib: before and after the 1st and 2nd dose of MK-3475. For MK-3475: Until 6 months after the last dose of MK-3475
|
Part 1: Pharmacokinetic (PK) parameters in Expansion cohort
Time Frame: For Pazopanib: before and after the 1st and 2nd dose of MK-3475. For MK-3475: Until 6 months after the last dose of MK-3475
|
Area under the plasma concentration-time curve from time 0 to 24 hrs (AUC[0-24], maximum observed concentration (Cmax), tmax, and concentration at 24 hours (C24) of pazopanib; Pre-dose (trough) concentration at the end of the dosing interval (Ctau), and apparent clearance following oral dosing CL/F of pazopanib will be determined if data permit.
|
For Pazopanib: before and after the 1st and 2nd dose of MK-3475. For MK-3475: Until 6 months after the last dose of MK-3475
|
Part 1 and Part 2: Overall response rate (ORR)
Time Frame: Average of 4 years
|
Overall response rate is defined as the percentage of subjects, who achieved either a confirmed complete response (CR) or partial response (PR) by RECIST v1.1 and modified RECIST
|
Average of 4 years
|
Part 1 and Part 2: Clinical benefit rate
Time Frame: Average of 4 years
|
Clinical benefit rate is defined as a confirmed response of CR or PR or at least 6-months stable disease by RECIST v1.1 and modified RECIST.
|
Average of 4 years
|
Part 1 and Part 2: Time to response
Time Frame: Average of 4 years
|
Time to response is defined for all subjects with a confirmed CR or PR as per RECIST v1.1as the time from randomization until the first documented evidence of CR or PR (whichever status is recorded first)
|
Average of 4 years
|
Part 1 and Part 2: Duration of response
Time Frame: Average of 4 years
|
Duration of response is defined for all subjects with confirmed CR or PR as the time from the first documented evidence of CR or PR until time of first documented disease progression or death due to any causes, whichever is first by RECIST v1.1 and modified RECIST
|
Average of 4 years
|
Part 2: PFS by modified RECIST
Time Frame: Average of 4 years
|
Average of 4 years
|
|
Part 1 and Part 2: Progression-free survival rate at 18 months (PFSR18)
Time Frame: 18 months
|
PFSR18 will be calculated based on Kaplan-Meier estimates of Progression-free survival (PFS) at 18 months by RECIST v1.1 and modified RECIST
|
18 months
|
Part 2: Overall survival (OS) at 18 months
Time Frame: 18 months
|
Overall survival at 18 months will be summarized based on the Kaplan-Meier method.
|
18 months
|
Part 2: Overall survival (OS)
Time Frame: Average of 4 years
|
Overall survival will be summarized using Kaplan-Meier survival curves
|
Average of 4 years
|
Part 2: Incidence and severity of AEs and SAEs
Time Frame: From the start of study treatment (first dose) and, until the post-treatment follow-up visit (at least 30 days after the last dose of investigational product) for AEs, and until 90 days after last dose for SAEs
|
From the start of study treatment (first dose) and, until the post-treatment follow-up visit (at least 30 days after the last dose of investigational product) for AEs, and until 90 days after last dose for SAEs
|
|
Part 2: Number of subjects with permanent discontinuation of treatment, dose reductions, interruptions, or delays
Time Frame: Average of 4 years
|
Average of 4 years
|
|
Part 2: Change from baseline in laboratory parameters
Time Frame: Average of 4 years
|
Laboratory assessments include haematology, clinical chemistry, urine, coagulation and thyroid function test
|
Average of 4 years
|
Part 2: Change from baseline in vital signs
Time Frame: Average of 4 years
|
Vital sign measurements will include heart rate, temperature and blood pressure
|
Average of 4 years
|
Part 2: Change from baseline in cardiac parameters
Time Frame: Average of 4 years
|
Cardiac assessments will include ECG and ECHOs
|
Average of 4 years
|
Part 2: Incidence and titer of anti MK 3475 antibodies in patients treated with pazopanib + MK 3475 and single-agent MK 3475
Time Frame: Until 6 months after the last dose of MK-3475
|
Subjects will be monitored for anti-MK 3475 antibodies throughout the study
|
Until 6 months after the last dose of MK-3475
|
Part 2: PK parameters in randomized phase
Time Frame: For Pazopanib: Until Dose 49 of MK-3475.
|
For analysis of plasma pazopanib and serum MK 3475 concentrations, blood samples will be collected from all subjects.
AUC[0-24], Cmax, tmax, and C24 of pazopanib alone and in combination with MK 3475; Cmax, Ctau, and apparent clearance following oral dosing CL/F of pazopanib will be determined if data permit.
|
For Pazopanib: Until Dose 49 of MK-3475.
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Carcinoma
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Pembrolizumab
Other Study ID Numbers
- 200249
- KEYNOTE-018 (Other Identifier: Merck)
- PZP034A2101 (Other Identifier: Novartis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Renal Cell
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Australian and New Zealand Urogenital and Prostate...RecruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell CarcinomaAustralia
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States, Taiwan, Australia
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
Australian and New Zealand Urogenital and Prostate...Bristol-Myers SquibbActive, not recruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation CarcinomaAustralia
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
-
AmgenCompletedRenal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell AdenocarcinomaFrance, United States, Germany
Clinical Trials on Pazopanib
-
Cure HHTUniversity of North CarolinaNot yet recruitingEpistaxis | Hereditary Hemorrhagic Telangiectasia
-
Illinois CancerCare, P.C.TerminatedNon Small Cell Lung CancerUnited States
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedMetastatic Renal Cell Carcinoma
-
Institut Claudius RegaudNovartisTerminatedMetastatic Cancer (Different Solid Tumour Types)France
-
Gynecologic Oncology GroupGlaxoSmithKlineWithdrawnUterine Leiomyosarcoma
-
Samsung Medical CenterCompletedRefractory Solid TumorsKorea, Republic of
-
Spanish Oncology Genito-Urinary GroupCompletedMetastatic Renal Cell CarcinomaSpain
-
GlaxoSmithKlineCompletedMacular DegenerationUnited States
-
Samsung Medical CenterCompletedLocally Advanced or Metastatic Non-clear Cell Type Renal Cell CarcinomaKorea, Republic of
-
Samsung Medical CenterCompletedNeuroendocrine TumorKorea, Republic of